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A B S T R A C T
Neuroblastoma is a challenging childhood malignancy, with a very high percentage of patients relaps-
ing following acquisition of drug resistance, thereby necessitating the identiﬁcation of mechanisms of
drug resistance as well as new biological targets contributing to the aggressive pathogenicity of the disease.
In order to investigate the molecular pathways that are involved with drug resistance in neuroblas-
toma, we have developed and characterised cisplatin resistant sublines SK-N-ASCis24, KellyCis83 and CHP-
212Cis100, integrating data of cell behaviour, cytotoxicity, genomic alterations and modulation of protein
expression. All three cisplatin resistant cell lines demonstrated cross resistance to temozolomide, etoposide
and irinotecan, all of which are drugs in re-initiation therapy. Array CGH analysis indicated that resis-
tant lines have acquired additional genomic imbalances. Differentially expressed proteins were identiﬁed
by mass spectrometry and classiﬁed by bioinformatics tools according to their molecular and cellular
functions and their involvement into biological pathways. Signiﬁcant changes in the expression of pro-
teins involved with pathways such as actin cytoskeletal signalling (p = 9.28E−10), integrin linked kinase
(ILK) signalling (p = 4.01E−8), epithelial adherens junctions signalling (p = 5.49E−8) and remodelling of
epithelial adherens junctions (p = 5.87E−8) pointed towards a mesenchymal phenotype developed by
cisplatin resistant SK-N-ASCis24. Western blotting and confocal microscopy of MYH9, ACTN4 and ROCK1
coupled with invasion assays provide evidence that elevated levels of MYH9 and ACTN4 and reduced
levels of ROCK1 contribute to the increased ROCK1-independent migratory potential of SK-N-ASCis24.
Therefore, our results suggest that epithelial-to-mesenchymal transition is a feature during the devel-
opment of drug resistance in neuroblastoma.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Neuroblastoma, a paediatric cancer of the sympathetic nervous
system, is characterised by a highly heterogeneous clinical behaviour,
ranging from spontaneous regression to rapid progression and patient
death [1]. The clinical course depends on the molecular character-
istics of the tumor, patient age, disease stage, and states of
differentiation. Patients with high risk disease (tumours with either
MYCN ampliﬁcation or deletions on the long arm of chromosome
11, large numbers of segmental chromosomal imbalances, stage 4
disease) still have relatively low overall survival rates (~40%) in spite
of intensive multimodal chemotherapy. The initial induction
chemotherapy often includes a combination of cisplatin, vincris-
tine, carboplatin, etoposide and cyclophosphamide. Surgery, radiation
and myeloablative treatments using escalating chemotherapeutic
combinations followed by bone marrow infusion are also used on
high-risk cases. Post-initiation treatment patients are routinely pre-
scribed 13-cis-retinoic acid (RA) as a maintenance therapy for 6
months and immunotherapy with the chimeric anti-GD2 anti-
body ch14.18, both of which have led to improved event free survival
[2]. Nevertheless, the 5 year survival rate is only ~15% for patients
with relapse disease who were originally diagnosed with high risk
neuroblastoma, in spite of treatment with additional drugs such as
topotecan and temozolomide [3], presumably due to the develop-
ment of multi-drug resistance.
Relapse disease with the emergence of drug resistant tumour
cells is a major impediment to the successful treatment of high risk
neuroblastoma patients. The development of drug resistance
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involves the acquisition of multiple genetic and epigenetic changes
leading to aberrant RNA and protein expression. These changes affect
many pathways, including those that alter the cytoskeleton, copper
metabolism, cell surface presentation of proteins and epithelial-
to-mesenchymal transition (EMT). It is not surprising therefore that
several mechanisms mediating chemotherapeutic resistance have
been identiﬁed, including decreased drug uptake by the solute carrier
family of transporters, increased drug eﬄux from cells by the ad-
enosine triphosphate-binding cassette family of membrane transport
proteins, gain in DNA damage repair mechanisms and failure of the
cell death pathways (detailed in [4]).
Acquired or innate resistance to chemotherapeutic agents is the
single most important factor leading to therapy failure and recur-
rence of malignant disease. Thus, the identiﬁcation of new biological
targets that facilitate early diagnosis and/or contribute to the ag-
gressive pathogenicity of this disease, along with the development
of reagents that will interfere with the function of these targets, is
a prerequisite for improving patient survival.
In order to identify further molecular pathways that are in-
volved with drug resistance in neuroblastoma, we have developed
cisplatin resistant sublines of SK-N-AS, Kelly and CHP-212 cell lines.
Cisplatin activates apoptosis by forming DNA intrastrand cross-
links known as platinum-DNA adducts [4]. Cisplatin acts on several
signalling pathways, triggering mechanisms that are involved in re-
sistance development by establishing a complicated self-defence
system to escape exogenous cytotoxic compounds of different origins.
In the work presented here, we report proteomic proﬁling of each
of these drug resistant lines and their respective drug sensitive pa-
rental line. The SK-N-AS resistant subline, SK-N-ASCis24, was shown
to have increased resistance to apoptosis through increased ex-
pression of the neuronal apoptosis inhibitory protein (NAIP) gene
through a combination of DNA copy number gain and reduced
miRNA signalling [5]. Here, we show through proteomic proﬁling
and functional studies that the SK-N-ASCis24 variant has under-
gone an epithelial-to-mesenchymal transition in addition to acquiring
a drug resistant phenotype.
Materials and methods
Cell culture and transfections
CHP-212 is a MYCN ampliﬁed cell line derived from a kidney mass from a 20
month old male infant whose INSS disease stage is unknown. The Kelly cell line is
a MYCN ampliﬁed cell line with a 17q chromosomal gain. The SK-N-AS cell line is a
MYCN diploid cell line derived from the metastatic bone marrowmass of INSS stage
4 disease of an 8 year old female. It has a deletion at chromosome 1p and 11q as
well as a gain at 17q.
CHP-212, Kelly and SK-N-AS cell lines were obtained from the European Cell
Culture Collection. CHP-212 cells were cultured in a 1:1 mixture of Eagle’s Minimum
Essential Medium (Gibco, #21090-022) and Ham’s F12 Medium (Gibco, #21765-
029), 1% Non-essential Amino Acids (Gibco, #11140-050), 200mMGlutamine (Gibco,
#25030-024), 10% Foetal Bovine Serum (Gibco, #10270106), 1% Penicillin/Streptomycin
(Gibco, #15070). Kelly cells were cultured in RPMI (Gibco, #21875-034), 10% Foetal
Bovine Serum (Gibco, # 10270106), 1% Penicillin/Streptomycin (Gibco, #15070). SK-
N-AS cells were cultured inMEM (Gibco, #21090-022), 1% Non-essential Amino Acids
(Gibco, #11140-050), 200 mM Glutamine (Gibco, #25030-024), 10% Foetal Bovine
Serum (Gibco, #10270106), 1% Penicillin/Streptomycin (Gibco, #15070). All cell lines
were incubated at 37 °C in a humidiﬁed chamber with 5% CO2. The chemotherapy
resistant sub-lines were selected by exposing cells to increasing concentrations of
cisplatin over a 6 month period as described previously for SK-N-AS [5]. Cells were
routinely screened formycoplasma usingMycoAlert Mycoplasma Detection kit (Lonza,
#LT07-318). Cell lines were authenticated by STR PCR (SOP ECACC/047).
MTT assay
Cells were seeded at 1 × 104 cells/mL suspension in 96-well plates at 100 μL/well
and incubated overnight at 37 °C in 5% CO2. The following cytotoxic drugs were used
in this study: Cisplatin (Hospira UK, #PA437/4/7), Etoposide (Ebewe Pharma, #pa789/
13/1), Temozolomide (Sigma-Aldrich, #T2577) and Irinotecan (Sigma-Aldrich, #I1406).
Cytotoxic drug was added in a serial dilution and cell growth was monitored over
5–7 days. Assessment of cell viability was determined using an acid phosphatase
assay as previously described [5].
Array comparative genomic hybridisation
aCGH was carried out as previously described [6] using a 72,000 feature array
(NimbleGen).
Cell lysis
Preparations of cell lysates for proteomic analysis were repeated in identical con-
ditions of cell growth. Cells were harvested when they reached a 75–80% conﬂuence
in T75 culture ﬂasks in complete media.
The cell pellet was resuspended in lysis buffer (50 mM Tris, pH 8, 150 mM NaCl,
2% NP-40, 0.5% sodium deoxycholate and 0.1% SDS). Lysis of cells was also aided by
three freeze–thaw cycles in liquid nitrogen. Protein lysates were clariﬁed by cen-
trifugation (16,000 × g, 40 min, 4 °C). Protein concentration was determined by
Coomassie (Bradford) Protein Assay Kit (Pierce, # 23200).
Mass spectrometry
Digested samples were resuspended in 0.1% TFA in 2% ACN (Fluka, #34976-2.5L-
R) and analysed by nanoLC-MS/MS using an Ultimate 3000 system (Dionex) coupled
to a nanospray LTQ Orbitrap mass spectrometer (Thermo Fisher Scientiﬁc), using a
linear ACN gradient from 0% to 65% CAN (Sigma, #84378-1L) over 180 min. Buffers
used for nano-LC separation contained 0.1% formic acid as the ion pairing reagent.
The ﬂow rate was 300 nL/min. The LTQ Orbitrap was operated in data-dependent
acquisition mode with Xcalibur software. Survey scan MS data were acquired in the
Orbitrap on the 300–2000m/zmass range with the resolution set to a value of 60,000
at 400m/z. The ﬁve most intense ions per survey scan were selected for MS/MS frag-
mentation and the resulting fragments were analysed in the linear trap. Collision
energy was set to 35%. Dynamic exclusion was employed within 60 s. Full scan mass
spectra were recorded in proﬁle mode and tandem mass spectra in centroid mode.
Biological replicates (n = 3) were analysed for each sample type.
Progenesis analysis
RAW ﬁles were analysed in Progenesis LC-MS software. This software extracts
quantitative information from MS1 data by aligning each LC–MS run to a reference
ﬁle. The results were ﬁltered based on statistical analysis. Any peptides with an ANOVA
score of p > 0.05 were eliminated. The MS2 data for the remaining peptides were
exported and the resulting MGF ﬁle was used to search the Swissprot database
(Release 2011_05) on theMASCOT server (www.matrixscience.com) for protein iden-
tiﬁcations. TheMascot parameters were (1) species, Homo sapiens, (2) allowed number
of missed cleavages, 1, (3) ﬁxed modiﬁcation, carboxylmethyl, (4) variable modiﬁ-
cations, methionine oxidation (5) peptide tolerance, ± 20 ppm, (6) MS/MS
tolerance, ± 0.6 Da and (7) peptide charge, + 2, +3 and +4. Peptides were also searched
against a decoy database to determine the false discovery rate (FDR).
The total number of statistically signiﬁcant peptides/features (p value ≤0.05) ex-
ported to Mascot for database searching was 877 (KellyCis83 versus Kelly), 1366 (SK-
N-ASCis24 versus SK-N-AS), and 1642 (CHP-212Cis100 versus CHP-212). Based on
these, a total of 118, 97 and 111 proteins (p value ≤0.05, a fold change ≥1.2, FDR ≤1%
and Mascot score>40) were identiﬁed respectively. Peptide conﬂicts were resolved
by assigning the peptide to the protein with the greater number of hits, a greater
Mascot score or a lower mass error; when conﬂicts could not be clearly resolved,
the peptide was excluded from the analysis.
Immunodetection
Total protein was analysed by western blotting using primary antibodies anti-
ACTN4 (Abcam, #ab32816), anti-MYL12B (Abcam, #ab137063), anti-MYH9 (Abcam,
#ab55456), anti-alpha-tubulin (Abcam, #ab7291), anti-beta-actin (Abcam, #ab6276),
anti-VIM (Cell Signaling Technology, #3295), Anti-Zeb1-[Anti-AREB6 antibody [3G6]-
N-terminal] (Abcam, #ab180905), Anti-Twist antibody [Twist2C1a] (Abcam,
#ab50887), and Anti-SNAIL antibody (Abcam, #ab180714), followed by anti-
mouse (Abcam, #ab6728) or anti-rabbit (Abcam, #ab97200) secondary antibody.
Immunoﬂuorescence staining was visualised using DAPI (Invitrogen, #D1306), anti-
mouse Alexa Flour®647 (Invitrogen, #A-21239) and anti-rabbit Alexa Flour®488
(Invitrogen, #A-11034) secondary antibody using a Leica SP2 AOBS confocal micro-
scope. Subsequent image processing was conducted using AutoquantX and
Metamorph.
Invasion assay
The 8 μm pore size PET BD BioCoatTM Growth Factor Reduced (GFR) MATRIGEL
Invasion Chambers (BD Biosciences, #354481) were used as per manufacturer’s in-
struction. Kelly cells were seeded at 105 cells per chamber while CHP-212 and SK-
N-AS cells were seeded at 0.5 × 105 cells per chamber. Brieﬂy, cell suspensions in
serum free culturemediawere added into the upper chamber of the insert. The bottom
chamber contained culture media containing 10% FBS. After a 48 hr incubation at
37 °C, 5% CO2 atmosphere, non-invading cells were removed, the inner side of the
insert was washed with PBS and the outer side was stained with 0.25% crystal violet
for 10 min. Inserts were then viewed under the microscope. Invading cells were
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counted by taking ten images at random points and manually counting cells, the
average of the ten images was then calculated.
Bioinformatics analysis
Bioinformatics analysis and annotations of the proteins identiﬁed were carried
out based on their biological functions and cellular localisations as per Human Protein
Reference Database (http://www.hprd.org), which is in compliance with Gene On-
tology standards.
Ingenuity Pathway Analysis (IPA, Ingenuity® Systems) was performed to outline
the most signiﬁcant canonical pathways and functions in the datasets. Detailed
methods for this procedure have been described previously [63].
In brief, identiﬁers from the datasets were uploaded into IPA and these were
mapped to the corresponding genes. These genes were overlaid onto the global mo-
lecular network developed from information contained in the Ingenuity Pathways
Knowledge Base. Networks of the genes in the dataset were then algorithmically
generated based on their connectivity. These networks were scored based on the
number of molecules included in the networks, with the score corresponding to the
negative logarithm of the p-value corresponding to the presence of these mol-
ecules in the network by chance. The signiﬁcance of the association between the
dataset and the canonical pathway was measured in two ways: (1) the ratio of the
number of genes from the dataset that map to a given canonical pathway was divided
by the total number of genes that map to the same canonical pathway; and (2) Fis-
her’s exact test was used to calculate a P-value to determine the probability that
the association between the genes in the dataset and the canonical pathway could
be explained by chance alone. After the datasets were uploaded, each gene identi-
ﬁer was mapped to its corresponding gene object in the IPA Knowledge Base, and
these genes were overlaid onto a global molecular network. Gene networks were
then algorithmically generated based on their connectivity.
Statistics
All statistical analysis was performed using GraphPad Prism 5 software (GraphPad
Software). The IC50 values were calculated by a non-linear least squares regres-
sion model to ﬁt the data to the log (inhibitor) versus response (variable slope).
Statistical signiﬁcance was assessed for a shift in IC50 of resistant cell line com-
pared to the parental using an actual dose of the drug nearest to the calculated IC50.
Statistical signiﬁcance was determined for all experimental data by using the
unpaired Student’s t-test. In all cases error bars are representative of the standard
deviation of the mean of three biological experiments unless otherwise stated. A
P-value of <0.05 was regarded as statistically signiﬁcant (* p < 0.05; ** P < 0.01;
*** P < 0.001).
Results
In order to identify the genetic pathways mediating drug resis-
tance in neuroblastoma, we developed and characterised 3 pairs of
sensitive and drug resistant neuroblastoma cell lines, integrating
data of cell behaviour, genomic alterations andmodulation of protein
expression.
Establishment and characterisation of cisplatin resistant CHP-212,
Kelly and SK-N-AS cell lines
The cisplatin resistant subline of SK-N-AS, SK-N-ASCis24, has re-
cently been described by Harvey et al. [5], and using similar methods
of pulse exposure to increasing concentrations of cisplatin over a
period of sixmonths, cisplatin resistant sublines for Kelly (KellyCis83)
and CHP-212 (CHP-212Cis100) were also developed. Initial dose for
all cell lines was 2 μM. Maximum doses for SK-N-AS, Kelly and CHP-
212 were 24 μM, 83 μM and 100 μM, respectively. The half maximal
inhibitory concentration (IC50) values of the six cell lines are
summarised in Table 1. A higher ﬁnal concentration for pulse se-
lection was necessary for CHP-212, as parental cells have a high
intrinsic resistance to cisplatin in comparison to SK-N-AS and Kelly
cells. As summarised in Table 1, each of the cisplatin resistant sub-
lines exhibited cross resistance to a number of other drugs used in
the neuroblastoma treatment regimen, including etoposide and
irinotecan. No signiﬁcant cross resistance was detected to
temozolomide. Differences in cell morphology were also observed
between cisplatin resistant and parental cells by phase contrast mi-
croscopy (Fig. 1A). This was most notable for SK-N-ASCis24 cells,
which became more elongated in comparison with the polygonal
morphology of the parental cell line. Array CGH analysis indicated
that all of the resistant lines have acquired additional genomic im-
balances (Supplementary File S1). The doubling time of drug resistant
cells differed from the parental lines, increasing for SK-N-ASCis24
and CHP-212Cis100 from 33 hrs to 74 hrs and from 48 hrs to 70 hrs,
respectively, while decreasing for KellyCis83 from 51 to 33 hrs. A
signiﬁcant increase in the invasive ability was observed for CHP-
212Cis100 (2.8-fold change) and SK-N-ASCis24 (2.5-fold change)
(Fig. 1D). No signiﬁcant change in the invasiveness of KellyCis83 was
detected.
Proteomic proﬁling of cisplatin sensitive and resistant human
neuroblastoma cells
Comparative proteomic analysis using label free mass spectrom-
etry was carried out on each parental and drug resistant cell line
in triplicate. A total of 111 signiﬁcant (p ≤ 0.05, fold change ≥ 1.2)
protein expression changes were registered in the CHP-212Cis100
resistant cell line, 118 in KellyCis83, and 97 in SK-N-ASCis24 (Fig. 1B),
when compared to their sensitive parental lines. More proteins were
up-regulated than down-regulated in CHP-212Cis100 relative to pa-
rental cells, whereas the opposite occurred in KellyCis83 and SK-
N-ASCis24 (Fig. 2C). A full list of protein abundance changes detected
for each cell line as well as MS data are available in Supplementary
File S2. Out of a total 326 identiﬁed proteins, 73 were differen-
tially expressed in two out of three datasets, 35 of which were
differentially expressed in the same direction in at least two drug
resistant cell lines (Table 2). Only B-tubulin (TUBB) was differen-
tially expressed in all three cell lines in the same direction
(under-expressed).
Classiﬁcation of modulated proteins in cisplatin-sensitive and
resistant neuroblastoma cell lines by ingenuity pathway analysis
To answer the question of whether the development of cisplatin
resistance involves similar type of proteins, we used Ingenuity
Pathway Analysis software (IPA) to analyse the differentially ex-
pressed proteins for each individual cell line pair. The analysis
for ‘molecular and cellular functions’ indicated that the top scoring
function was cellular growth and proliferation, followed by cell
death and survival (Fig. 2A and Table 3), both consistent with
Table 1
IC50 values of six cell lines. The value of IC50 of the sensitive and resistant cells to the tested drugs.
Cell line Cisplatin Fold
resistance
p value Etoposide Fold
resistance
p value Irinotecan Fold
resistance
p value Temozolomide Fold
resistance
p value
Kelly 1.40 ± 0.25 1 0.12 ± 0.01 1 0.18 ± 0.02 1 139.20 ± 5.95 1
KellyCis83 2.45 ± 0.40 1.75 0.0001 0.16 ± 0.02 1.33 0.004 0.37 ± 0.04 2.0 0.002 251.00 ± 15.75 1.80 0.09
SK-N-AS 0.68 ± 0.09 1 0.24 ± 0.03 1 0.82 ± 0.07 1 227.70 ± 22.15 1
SK-N-ASCis24 3.60 ± 0.57 5.3 0.00002 0.57 ± 0.11 2.25 0.004 4.40 ± 0.98 5.37 0.007 480.60 ± 101.15 2.11 0.09
CHP-212 2.25 ± 0.24 1 N/D 0.37 ± 0.05 1 7.97 ± 0.69 1
CHP-212Cis100 2.50 ± 0.37 1 N/D 0.70 ± 0.17 1.89 9.55 ± 0.88 1.2
Values are means ± SD. N/D, not determined due to high intrinsic drug resistance.
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acquisition of a chemotherapeutic drug resistant phenotype. IPA anal-
ysis for canonical pathway analysis identiﬁed the top 5 pathways
for each cisplatin resistant cell line pair (Fig. 2B). Of these, four path-
ways were common for SK-N-ASCis24 and CHP-212Cis100, while
KellyCis83 did not share as many similarities. Only the pathway ‘Al-
dosterone Signaling in Epithelial Cells’ was common for KellyCis83
and CHP-212Cis100. IPA analysis for gene networks identiﬁed genes
involved in DNA replication, recombination and repair, RNA post tran-
scriptional modiﬁcation, cellular movement and organisation, and
inﬂammatory response (Table 4). All of the above support the concept
that drug resistant cells can overcome cytotoxic pressure and adapt
through establishment of complicated defence mechanisms which
would be unique for each drug resistant tumour [7].
Cisplatin regulator analysis
To explore the possible molecular mechanisms underlying
cisplatin resistance, upstream regulator analysis was carried
out on the complete datasets of modulated proteins using IPA soft-
ware. The upstream regulator analysis predicts upstreammolecules,
A B
SK-N-ASCis24    
CHP-212Cis100
KellyCis83
SK-N-AS
CHP-212
Kelly
C
D
CHP-212Cis100 vs CHP-212
KellyCis83 vs Kelly
SK-N-ASCis24 vs SK-N-AS
CHP-212Cis100
SK-N-ASCis24
Fig. 1. (A) Morphology changes in cisplatin resistant and corresponding parental cell sub-line. Light phase contrast microscopy, bar 50 μm. (B) Quantitative Venn diagram
of the number of identiﬁed proteins in three cisplatin resistant cell lines specifying the number of common and exclusively expressed proteins. (C) Summary of down and
upregulated proteins across three cisplatin resistant cell lines. (D) Assessment of in vitro invasion of CHP-212Cis100 and CHP-212, KellyCis83 and Kelly, SK-N-ASCis24 and
SK-N-AS. Graphed data represent mean values ± SD of three independent experiments. Asterisks indicate statistical signiﬁcance obtained using a paired Student’s t-test.
* p < 0.05, ** p < 0.01, ***p < 0.001, n = 3 for all experiments.
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includingmicroRNA and transcription factors, whichmay be causing
the observed gene expression changes. Known mutual interac-
tions among differentially expressed proteins for each cell line pair
were used to construct protein networks ranked by score (Fig. 3).
Nine proteins in the cisplatin regulator network were predicted in
CHP-212Cis100, 11 in KellyCis83 and 12 in SK-N-ASCis24. Cisplatin
regulator network activation z-scores were not signiﬁcant, −1.029
for CHP-212Cis100, −0.093 for KellyCis83, and 0.637 for SK-N-
ASCis24. Four proteins were in common across these networks, beta-
tubulin (TUBB), beta-actin (ACTB), vimentin (VIM) and 78 kDa
glucose-regulated protein (HSPA5). TUBB had altered expression in
the same direction in all drug resistant cells. The rest did not display
the same pattern. Increases in VIM expression in SK-N-ASCis24 and
CHP-212Cis100 pointed towards a possible epithelial to mesenchy-
mal transition during the development of cisplatin resistance.
Epithelial to mesenchymal transition
A large number of cytoskeletal proteins were identiﬁed as having
an altered abundance in cisplatin-resistant neuroblastoma cells. Sig-
niﬁcant modiﬁcations in the abundance of cytoskeletal proteins that
are consistent with changes associated with epithelial-to-
mesenchymal transition (EMT) [8–10] were registered in SK-N-
ASCis24 and CHP-212Cis100. These include decreases in cytokeratin
proteins (KRT18 and KRT8) and increases in vimentin (VIM) (Table 2).
In the case of KellyCis83, a decrease in VIM and no changes in KRT18
and KRT8 were found. The changes in cytoskeletal EMT markers
prompted us to examine the expression of known EMT transcrip-
tion factors SNAI1, ZEB1 and TWIST1 across all three cell line pairs
(Fig. 4). Interestingly, the pattern of expression for these three tran-
scription factors was different in parental sensitive cell lines. Kelly
and SK-N-AS had higher expression levels of TWIST1 and SNAI1 than
ZEB1, while CHP-212–ZEB1 than SNAI1. Loss in the expression of
ZEB1 was detected across all resistant cell lines. The resistant CHP-
212Cis100 displayed a signiﬁcant increase of SNAI1 and a decrease
of TWIST1 compared to the parental cell line. No change in the levels
of SNAI1 and TWIST1 was demonstrated in KellyCis83 and Kelly. The
resistant SK-N-ASCis24 displayed signiﬁcantly lower levels of SNAI1
and TWIST1.
Mesenchymal phenotype of SK-N-ASCis24
As previously mentioned, SK-N-ASCis24 had dramatic changes
in its cellular morphology (Fig. 1A), signiﬁcant modiﬁcations in the
abundance of cytoskeletal EMTmarkers, as well as signiﬁcant modi-
ﬁcations in the expression of proteins involved with pathways such
as actin cytoskeletal signaling (p = 9.28E−10), integrin linked kinase
(ILK) signaling (p = 4.01E−8), epithelial adherens junctions signal-
ling (p = 5.49E−-8) and remodelling of epithelial adherens junctions
(p = 5.87E−8) (Fig. 2). All these pathways involve proteins belong-
ing to integrin, actin and myosin families (Fig. 5A). The differential
expression for a number of proteins from Fig. 3A has been vali-
dated by western blot analysis (Fig. 5B). Proteins of the actin–
myosin axes play important roles in mesenchymal cell migration
[11], and it is of interest that the SK-N-ASCis24 exhibits a very sig-
niﬁcant increase in migration potential relative to the parental line
(Fig. 1D). All of the above suggests that the cisplatin resistant neu-
roblastoma cell line SK-N-ASCis24 has acquired a mesenchymal
phenotype.
One of the most signiﬁcant IPA networks that impacted in SK-
N-ASCis24 was ‘Cellular movement, nervous system development
and function, cellular function and maintenance’ (Table 4). MYH9,
which is known to play an important role in cell motility and in-
vasiveness [12,13], was signiﬁcantly up-regulated in SK-N-ASCis24
based on mass spectrometry (Table 2) and western blot (Fig. 5B).
Over-expression of MYH9was also detected by immunohistochemi-
cal staining of cells (Fig. 5). ROCK/ROK/Rho kinases are alsomembers
of the same IPA network as MYH9 (Table 4), and a physical inter-
action between ROCK1 andMYH9 has been demonstrated [14]. There
was no indication by mass spectrometry analysis that ROCK1 ex-
pression was modulated in SK-N-ASCis24, although western blot
analysis (Fig. 5D–E) and immunohistochemical staining of cells
A B
CHP-212Cis100
SK-N-ASCis24
KellyCis83
Fig. 2. IPA classiﬁcation of proteomic data. (A) Classiﬁcation summary of molecular and cellular functions predicted by IPA. The top 5 functions for each cisplatin resistant
cell line were compared. (B) Classiﬁcation summary of canonical pathways predicted by IPA. The top pathways for each cisplatin resistant cell line were compared. The
total bar length is proportional to p value and presented as –log(p value). Coloured blocks next to each function are coded according to cisplatin resistant cell line. Brown
– KellyCis83, orange – SK-N-ASCis24 and khaki – CHP-212Cis100.
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Table 2
Signiﬁcantly differentially modulated proteins in cisplatin resistant cell lines in comparison with parental identiﬁed by label-free LC-MS.
Accession Symbol ID CHP-212Cis100 versus CHP-212 KellyCis83 versus Kelly SK-N-ASCis24 versus SK-N-AS
Fold change Modulation p value Fold change Modulation p value Fold change Modulation p value
P24752 ACAT1 Acetyl-CoA acetyltransferase 1.53 ↑ 0.0393088 0.69 ↓ 0.0249396
P60709 ACTB Actin, cytoplasmic 1 0.75 ↓ 0.0027265 0.49 ↓ 0.0271745 1.39 ↑ 0.0016375
P12814 ACTN1 Alpha-actinin-1 0.37 ↓ 0.0019869 3.1 ↑ 0.0036693
O43707 ACTN4 Alpha-actinin-4 0.68 ↓ 1.315E-05 2.02 ↑ 0.0104785
Q09666 AHNAK Neuroblast differentiation-
associated protein AHNAK
1.48 ↑ 0.0054692 0.22 ↓ 2.134E-05
P25705 ATP5A1 ATP synthase subunit alpha 2.15 ↑ 0.0019666 1.49 ↑ 0.0176348
P06576 ATP5B ATP synthase subunit beta 1.66 ↑ 0.0097048 1.35 ↑ 0.0310778
P80723 BASP1 Brain acid soluble protein 1 0.68 ↓ 0.0008676 3.6 ↑ 0.0057143
Q5T1J5 CHCHD2P9 Putative coiled-coil-helix-
coiled-coil-helix domain-
containing protein CHCHD2P9
1.65 ↑ 0.0142642 1.35 ↑ 0.0199838 0.28 ↓ 0.0043879
Q96EP5 DAZAP1 DAZ-associated protein 1 1.93 ↑ 0.0031706 0.63 ↓ 0.0467999
P60842 EIF4A1 Eukaryotic initiation factor
4A-I
1.55 ↑ 0.0001166 0.43 ↓ 0.04885
P06733 ENO1 Alpha-enolase 0.61 ↓ 0.0460728 1.47 ↑ 0.0023987
P07954 FH Fumarate hydratase 1.38 ↑ 0.0173403 0.58 ↓ 0.0053465
Q96AE4 FUBP1 Far upstream element-binding
protein 1
1.47 ↑ 0.0111813 0.62 ↓ 0.0317052
Q14697 GANAB Neutral alpha-glucosidase AB 1.44 ↑ 0.0241526 0.49 ↓ 0.0174452
P04406 GAPDH Glyceraldehyde-3-phosphate
dehydrogenase
0.72 ↓ 0.0231004 1.46 ↑ 0.0006592 0.51 ↓ 0.0046544
P0C0S8 HIST1H2AG Histone H2A type 1 1.7 ↑ 0.00082 0.78 ↓ 0.0499551 0.51 0.0299902
P62805 HIST1H4A Histone H4 1.61 ↑ 0.0004494 0.5 ↓ 0.027698
Q8N257 HIST3H2BB Histone H2B type 3-B 1.94 ↑ 0.0083345 0.62 ↓ 0.0070192
P09651 HNRNPA1 Heterogeneous nuclear
ribonucleoprotein A1
1.52 ↑ 0.023185 0.57 ↓ 0.0006651
P22626 HNRNPA2B1 Heterogeneous nuclear
ribonucleoproteins A2/B1
1.6 ↑ 0.0005425 1.37 ↑ 0.0145846
P51991 HNRNPA3 Heterogeneous nuclear
ribonucleoprotein A3
2.29 ↑ 0.0012889 0.06 ↓ 0.0218785
Q14103 HNRNPD Heterogeneous nuclear
ribonucleoprotein D0
1.53 ↑ 0.0001069 0.41 ↓ 0.0040732
P31942 HNRNPH3 Heterogeneous nuclear
ribonucleoprotein H3
1.51 ↑ 0.0022061 0.69 ↓ 0.0227652
P61978 HNRNPK Heterogeneous nuclear
ribonucleoprotein K
1.45 ↑ 0.0011688 1.32 ↑ 0.0135432 0.7 ↓ 0.0149234
P52272 HNRNPM Heterogeneous nuclear
ribonucleoprotein M
1.59 ↑ 0.0026679 1.35 ↑ 0.0269281 0.69 ↓ 0.0055936
Q00839 HNRNPU Heterogeneous nuclear
ribonucleoprotein U
1.57 ↑ 0.0088573 0.6 ↓ 0.0095268
P08238 HSP90AB1 Heat shock protein HSP 90-
beta
1.27 ↑ 0.0215486 1.24 ↑ 0.0022558
P11021 HSPA5 78 kDa glucose-regulated
protein
1.38 ↑ 0.0014272 0.62 ↓ 0.039906 3.18 ↑ 0.0072475
P38646 HSPA9 Stress-70 protein 1.59 ↑ 1.751E-07 0.62 ↓ 0.007537
P04792 HSPB1 Heat shock protein beta-1 0.43 ↓ 0.0003869 0.42 ↓ 0.0264504
P10809 HSPD1 60 kDa heat shock protein 1.75 ↑ 0.0001189 0.78 ↓ 0.0075304
P61604 HSPE1 10 kDa heat shock protein 2.04 ↑ 0.0047056 0.69 ↓ 0.0237272
Q92945 KHSRP Far upstream element-binding
protein 2
1.6 ↑ 0.0056766 0.57 ↓ 0.0237794
P52292 KPNA2 Importin subunit alpha-2 3.28 ↑ 0.0043833 1.98 ↑ 0.0342929
P05783 KRT18 Keratin, type I cytoskeletal 18 0.11 ↓ 3.135E-05 0.12 ↓ 0.0003971
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Table 2 (continued)
Accession Symbol ID CHP-212Cis100 versus CHP-212 KellyCis83 versus Kelly SK-N-ASCis24 versus SK-N-AS
Fold change Modulation p value Fold change Modulation p value Fold change Modulation p value
P05787 KRT8 Keratin, type II cytoskeletal 8 0.07 ↓ 3.173E-10 0.05 ↓ 0.0068007
P00338 LDHA L-lactate dehydrogenase A
chain
1.23 ↑ 0.0137737 0.5 ↓ 0.0297607
P07195 LDHB L-lactate dehydrogenase B
chain
0.56 ↓ 0.0009125 0.29 ↓ 0.0084766
P46821 MAP1B Microtubule-associated
protein 1B
1.34 ↑ 0.0065255 1.63 ↑ 0.0078873
P40926 MDH2 Malate dehydrogenase 1.67 ↑ 0.0188808 1.54 ↑ 0.0069937
P35579 MYH9 Myosin-9 0.6 ↓ 0.027779 4.27 ↑ 0.0040361
O14950 MYL12B Myosin regulatory light chain
12B
0.5 ↓ 0.0259878 3.03 ↑ 0.0132585
P60660 MYL6 Myosin light polypeptide 6 0.69 ↓ 0.0110096 2.54 ↑ 0.0028463
Q15843 NEDD8 NEDD8 0.52 ↓ 0.0355481 0.32 ↓ 0.0270897
Q15233 NONO Non-POU domain-containing
octamer-binding protein
1.6 ↑ 4.498E-05 0.7 ↓ 0.014344
P06748 NPM1 Nucleophosmin 1.34 ↑ 0.0060107 1.31 ↑ 0.0025631
P07237 P4HB Protein disulﬁde-isomerase 0.48 ↓ 0.0259334 3.17 ↑ 0.0067148
P30101 PDIA3 Protein disulﬁde-isomerase
A3
0.58 ↓ 0.0001215 0.71 ↓ 0.041118 2.94 ↑ 0.0120008
Q15084 PDIA6 Protein disulﬁde-isomerase
A6
0.62 ↓ 0.0460694 2.16 ↑ 0.0171422
P07737 PFN1 Proﬁlin-1 0.62 ↓ 0.0087943 1.58 ↑ 0.0021374 0.35 ↓ 0.0169905
P00558 PGK1 Phosphoglycerate kinase 1 1.48 ↑ 0.0295475 0.47 ↓ 0.0380779
P35232 PHB Prohibitin 1.75 ↑ 0.0087227 0.71 ↓ 0.0037858 0.32 ↓ 0.0075181
P14618 PKM Pyruvate kinase isozymes M1/
M2
0.66 ↓ 0.0018889 1.49 ↑ 0.0111613
Q06830 PRDX1 Peroxiredoxin-1 1.49 ↑ 0.0066261 0.03 ↓ 0.0315948 0.64 ↓ 0.0301092
P30041 PRDX6 Peroxiredoxin-6 0.71 ↓ 0.0390701 0.53 ↓ 0.0101555
P62979 RPS27A Ubiquitin-40S ribosomal
protein S27a
0.51 ↓ 0.0334092 1.56 ↑ 0.0180621
P08865 RPSA 40S ribosomal protein 1.58 ↑ 0.0140854 0.67 ↓ 0.00124
P82979 SARNP SAP domain-containing
ribonucleoprotein
0.73 ↓ 0.0372508 0.67 ↓ 0.0050523
P23246 SFPQ Splicing factor, proline- and
glutamine-rich
1.82 ↑ 0.0106231 1.46 ↑ 0.0395062
Q01082 SPTBN1 Spectrin beta chain, non-
erythrocytic 1
0.54 ↓ 0.0004211 1.68 ↑ 0.0007724
Q9UJZ1 STOML2 Stomatin-like protein 2 4.31 ↑ 0.0004175 0.65 ↓ 0.0141966
P29401 TKT Transketolase 0.29 ↓ 9.695E-05 0.58 ↓ 0.0001948
P60174 TPI1 Triosephosphate isomerase 1.58 ↑ 0.0020865 0.48 ↓ 0.0301769
Q9BQE3 TUBA1C Tubulin alpha-1C chain 0.77 ↓ 0.0031913 0.6 ↓ 0.0164661
P07437 TUBB Tubulin beta chain 0.78 ↓ 0.0455105 0.35 ↓ 0.000303 0.37 ↓ 0.0423107
Q15819 UBE2V2 Ubiquitin-conjugating
enzyme E2 variant 2
0.59 ↓ 0.0090759 0.32 ↓ 0.0474067
P18206 VCL Vinculin 0.53 ↓ 0.0088382 0.56 ↓ 0.0260816
P55072 VCP Transitional endoplasmic
reticulum ATPase
1.9 ↑ 0.0067195 0.58 ↓ 0.0048664
P08670 VIM Vimentin 1.33 ↑ 0.0224295 0.07 ↓ 0.0007459 4.83 ↑ 0.0040634
P13010 XRCC5 X-ray repair cross-
complementing protein 5
4.78 ↑ 0.0012141 0.7 ↓ 0.0204185
P61981 YWHAG 14-3-3 protein gamma 0.68 ↓ 6.034E-05 0.74 ↓ 0.0433372
P63104 YWHAZ 14-3-3 protein zeta/delta 0.7 ↓ 0.0406417 0.7 ↓ 0.0282821
148
O
.Piskareva
et
al./Cancer
Letters
364
(2015)
142–155
(Fig. 5F) indicated a lower level of expression of ROCK1, whichmight
be consistent with the mesenchymal phenotype, as will be dis-
cussed later.
Discussion
Whether pre-existent (intrinsic), or induced by treatment (ac-
quired), drug resistance involves complex changes at both genetic
and epigenetic levels. These can vary across different cancers and
present themajor impediment to the successful treatment of disease.
Understanding the pathophysiology underlying intrinsic or ac-
quired resistance will be paramount to stratifying patients into
subgroups and subsequent design of new therapies and treat-
ment regimens. This is particularly important for neuroblastoma,
which is a highly heterogeneous disease where recurrence and pro-
gression is very common in spite of intensive multimodal therapy
[1].
Several groups have developed drug resistant neuroblastoma cell
lines in order to elucidate the mechanisms and key players in-
volved in this process. To date, 14 clinically relevant drug resistant
neuroblastoma cell lines have been published [5,15–22]. Unfortu-
nately, it is diﬃcult to make a direct comparison between them as
they have very little overlapping characterisation.
In the present study, we characterised three cisplatin resistant
neuroblastoma cell lines to gain insights in similarities and differ-
ences between them. The morphological and growth characteristics
were documented for the three resistant cell lines. Of these, SK-N-
ASCis24 underwent themost dramaticmorphological changes during
the development of drug resistance, and themost signiﬁcant changes
in cell invasiveness. Similarly, signiﬁcant morphology changes
were observed for UKF-NB-2 resistant derivatives [16,18]. The fact
that the doubling time of SK-N-ASCis24 was signiﬁcantly higher in-
dicates that the invasive potential of the cells was altered, as opposed
to an increase in the number of cells available to cross the
Table 3
List of proteins identiﬁed in top scoring molecular and cellular functions predicted by IPA.
Function Name p-value Molecules
Cellular growth and
proliferation
CHP-212Cis100 5.54E−10 HNRNPL, SRSF2, DBN1, NPM1, PFN1, S100A11, GNB2L1, SFPQ, HSPA5, TUBB, LMNB1, CACYBP, HNRNPA1,
TARDBP, HNRNPF, YWHAG, CFL1, ATP5A1, RPL23A, SRSF3, CBX1, ATP5B, LMNB2, ZYX, ACTN4, VDAC1, XRCC5,
HNRNPAB, RPSA, SPTBN1, PRDX1, PDIA3, HNRNPA2B1, PKM, HNRNPK, UCHL1, PHB, HSP90AB1, AHNAK, FLNA,
ANXA1, VCP, VCL, NCL, HNRNPC, ACTN1, HNRNPU, ACTB, G6PD, VIM, HNRNPD, HSPD1, ACLY, HNRNPM, ENO1,
KRT8, DAZAP1, SERPINH1, EIF4A1, ACAT1, MYH9
KellyCis83 2.97E−04 CHGA, PFN1, EML4, CCT2, RAN, UBE2V2, SFPQ, TUBB, HSPA5, EIF3C/EIF3CL, STMN1, ENAH, PGK1, CDC37,
EWSR1, ATP5A1, CLTC, PFDN5, HSPA8, PTBP1, ATP5B, FSCN1, XRCC5, GSTP1, RPSA, PRDX2, PEBP1, NME1,
PRDX1, PDIA3, KPNA2, PKM, EEF1B2, DDX17, IGF2BP1, HNRNPK, HSP90AB1, PHB, VCP, PFN2, HNRNPU, TRIM28,
VIM, HSPD1, HNRNPM, ENO1, GPI, ACAT1, CCT7, GAP43
SK-N-ASCis24 5.04E−08 NPM1, TPD52L2, PFN1, SEPT9, NME2, UBE2V2, HSPA5, TUBB, CTSD, HNRNPA1, FASN, S100A10, PGK1, YWHAG,
PLEC, LMNA, NASP, LIMA1, SPTAN1, ACTN4, CTTN, LDHA, SPTBN1, PRDX1, PDIA3, KPNA2, HNRNPA2B1, NAA10,
HNRNPK, PHB, AHNAK, HNRNPR, VCL, ACTN1, ITGB1, CALR, PTMA, ACTB, ITGA2, VIM, HNRNPD, NAP1L1,
HNRNPM, COL1A1, ALB, KRT8, DAZAP1, NT5E, EIF4A1, CRABP2, CD44,MYH9
Cell death and survival CHP-212Cis100 9.59E−10 SRSF2, NPM1, S100A11, MAP1B, GNB2L1, SFPQ, HSPA5, TUBB, LMNB1, CACYBP, HNRNPA1, TARDBP, P4HB,
YWHAG, CFL1, ATP5A1, HSPA9, YWHAZ, STOML2, HSP90AA1, ZYX, KRT18, ACTN4, AARS, FH, VDAC1, XRCC5,
RPSA, HSPB1, HSD17B10, SPTBN1, FLNB, PDIA3, PRDX1, PKM, GAPDH, HNRNPK, PRDX6, ATP5H, UCHL1, PHB,
HSP90AB1, FLNA, ANXA1, ANXA5, HSPE1, VCP, VCL, NCL, HNRNPC, HNRNPU, ACTB, G6PD, VIM, HSPD1, ACLY,
ENO1, KRT8, ACAT1, MYH9
KellyCis83 2.44E−10 CHGA, EEF1A2, MAP1B, CCT2, RAN, UBE2V2, SFPQ, HSPA5, CBX5, TUBB, EIF3C/EIF3CL, VDAC2, STMN1, RUVBL2,
ALDOC, CDC37, EWSR1, YWHAE, EEF2, BLVRA, YWHAB, ATP5A1, HSPA9, BASP1, YWHAZ, PHB2, STOML2,
FUBP1, RANBP1, HSPA8, STIP1, ALDOA, FH, GSTP1, XRCC5, RPSA, PRDX2, PEBP1, NME1, PRDX1, PDIA3, KPNA2,
PKM, GAPDH, DDX17, EIF2S1, IGF2BP1, HNRNPK, CCT4, ALDH2, HSP90AB1, PHB, VCP, HSPE1, NEDD8, HNRNPU,
TRIM28, VIM, HSPD1, ENO1, GPI, ACAT1, CCT7, MAOA, PAFAH1B3
SK-N-ASCis24 1.29E−06 SPTBN1, NPM1, PRDX1, PDIA3, HLA-A, KPNA2, GAPDH, NME2, UBE2V2, KIAA1967, HSPA5, TUBB, HNRNPK,
PRDX6, CTSD, HNRNPA1, PHB, FASN, NEDD8, VCL, RPS3, ACTC1, S100A10, ITGB1, CALR, P4HB, PTMA, YWHAG,
ACTB, ITGA2, BASP1, PLEC, VIM, LMNA, FUBP1, COL1A1, ALB, KRT8, NT5E, CRABP2, CD44, MYH9, KRT18,
ACTN4, CNPY2, CTTN, LDHA, HSPB1
Cellular movement CHP-212Cis100 2.13E−06 HNRNPL, DBN1, NPM1, FLNB, PFN1, PRDX1, HNRNPA2B1, GNB2L1, MAP1B, PKM, HSPA5, LMNB1, HNRNPK,
HSP90AB1, PHB, FLNA, ANXA5, ANXA1, TUBA1C, VCL, NCL, CFL1, ACTB, G6PD, YWHAZ, VIM, HSPD1, KRT8,
MYL12B, ACAT1, HSP90AA1, ZYX, MYH9, LMNB2, ACTN4, FH, RPSA, HSPB1
KellyCis83 6.21E−03 PEBP1, DPYSL2, NME1, CHGA, PFN1, PRDX1, KPNA2, EEF1A2, PKM, MAP1B, CBX5, HSPA5, IGF2BP1, HNRNPK,
TUBB2B, STMN1, ENAH, HSP90AB1, PHB, YWHAE, YWHAZ, VIM, HSPD1, GPI, FLNC, FSCN1, ACAT1, ALDOA,
GAP43, FH, RPSA, MAOA
SK-N-ASCi24 1.91E−05 NPM1, PFN1, SEPT9, PRDX1, KPNA2, HNRNPA2B1, NME2, HSPA5, HNRNPK, CTSD, PHB, FASN, TUBA1C, VCL,
S100A10, ITGB1, CALR, PTMA, ACTB, ITGA2, PLEC, VIM, LMNA, COL1A1, ALB, KRT8, MYL12B, NT5E, LIMA1,
CD44, MYH9, ACTN4, CTTN, HSPB1
Cell-to-cell signaling and
interaction
CHP-212Cis100 2.66E−05 FLNB, SRSF2, DBN1, NPM1, PFN1, CFL1, ACTB, GNB2L1, VIM, UCHL1, KRT8, FLNA, ANXA1, ANXA5, ZYX, MYH9,
KRT18, VCL, ACTN4, ACTN1, RPSA
KellyCis83 3.53E−02 DPYSL2, GPI, NME1, CHGA, PDIA3, KPNA2, VIM, GAP43, MAOA
SK-N-ASCis24 1.38E−04 NPM1, PFN1, PDIA3, HLA-A, KPNA2, HSPA5, CTSD, VCL, ACTN1, S100A10, ITGB1, CALR, ACTB, ITGA2, PLEC, VIM,
COL1A1, KRT8, NT5E, LIMA1, CD44, MYH9, KRT18, ACTN4, SPTAN1, CTTN
Cellular development CHP-212Cis100 5.63E−05 HNRNPL, SPTBN1, FLNB, DBN1, NPM1, SRSF2, PFN1, PDIA3, MAP1B, PKM, GNB2L1, HNRNPA2B1, GAPDH, SFPQ,
HSPA5, TUBB, LMNB1, HNRNPK, UCHL1, CACYBP, HNRNPA1, HSP90AB1, PHB, FLNA, ANXA1, CALD1, TARDBP,
PHGDH, NCL, YWHAG, CFL1, ACTB, YWHAZ, G6PD, VIM, HSPD1, ACLY, SRSF3, ENO1, CBX1, KRT8, EIF4A1, ACAT1,
LMNB2, HSP90AA1, ACTN4, XRCC5
KellyCis83 9.89E−04 DPYSL2, PEBP1, CHGA, NME1, PFN1, PDIA3, KPNA2, MAP1B, CCT2, PKM, RAN, EEF1B2, SFPQ, DDX17, HSPA5,
TUBB, EIF3C/EIF3CL, HNRNPK, IGF2BP1, IDH1, STMN1, PHB, VCP, PFN2, CDC37, EWSR1, TRIM28, BASP1, PFDN5,
PTBP1, GPI, FSCN1, STIP1, ACAT1, GAP43, XRCC5, SEPT2, PRDX2
SK-N-ASCis24 1.04E−07 NPM1, PFN1, SEPT9, PDIA3, KPNA2, HNRNPA2B1, NME2, NAA10, TUBB, HSPA5, HNRNPK, CTSD, HNRNPA1, PHB
FASN, VCL, S100A10, ITGB1, PGK1, CALR, PTMA, YWHAG, ACTB, ITGA2, COL1A1, NASP, KRT8, EIF4A1, CRABP2,
CD44, ACTN4, SPTAN1, CTTN, LDHA
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membrane. Consistent with this observation is the fact that the
proteomics proﬁle showed an increase in several proteins that play
key roles in cytoskeletal structure and cell invasion. This includes
proteins of integrin (ITGB1, ITGA2), actin (ACTB, ACTN1, ACTN4,
ACTC1) and myosin (MYH9, MYL12B, MYL6) families.
KellyCis83 and SK-N-ASCis24 display levels of cisplatin resis-
tance comparable with that exhibited by neuroblastoma cell lines
derived from tumours at different phases of chemotherapy [23].
These resistance patterns correlated well with both treatment in-
tensities and drugs that the patients were administrated. Therefore,
drug resistant cell lines KellyCis83 and SK-N-ASCis24 exhibit clinically
relevant cisplatin resistant patterns. It appears that the SK-N-AS cell
line is more sensitive to cisplatin than the other tested drugs in our
study and as a result required lower doses of cisplatin to acquire
drug resistance. This observation is in agreement with Prochazka’s
study, where low doses of cisplatin were applied for the genera-
tion of another drug resistant SK-N-AS subline [15].
Cisplatin is known to induce cross resistance to a variety of drugs.
We examined cross resistance of cisplatin resistant neuroblas-
toma cell lines to combination drugs used in neuroblastoma
chemotherapy, namely temozolomide (alkylating agent), etoposide
and irinotecan (topoisomerase inhibitors). The IC50 values of the
Table 4
Top scoring network predicted by IPA. Proteins identiﬁed in our datasets are capitalised in bold.
Cell line Associated network Score Focus
molecules
Molecules in network
CHP-212Cis100 RNA post-transcriptional
modiﬁcation, connective tissue
disorders, metabolic disease
77 32 AHNAK, Akt, HIST2H2BF, HN1, HNRNPA1, HNRNPA2B1, HNRNPAB, HNRNPC, HNRNPD,
HNRNPF, HNRNPH1, HNRNPH3, HNRNPK, HNRNPL, HNRNPM, HNRNPU, HSPA9, KCTD12,
KHSRP, MAP1B, NCL, NONO, NPM1, p85 (pik3r), RBM14, Rnr, RPL23A, S100A16, SFPQ, SRSF2,
SRSF3, TARDBP, TKT, XRCC5, YWHAZ
Immunological disease,
dermatological diseases and
conditions, inﬂammatory
disease
37 20 AARS, ACTB, Actin, ACTN1, ACTN4, Alpha Actinin, Alpha catenin, ANXA1, ANXA5, CACYBP,
CALD1, CFL1, Coﬁlin, DBN1, ENO1, ERK1/2, F Actin, G-Actin, Lamin b, Mlc, MYH9, MYL6,
MYL12B, Myosin, PDGF (family), PFN1, Proﬁlin, Rock, S100A11, SPTBN1, TPM4, Tropomyosin,
trypsin, VCL, ZYX
Nucleic acid metabolism, small
molecule biochemistry, DNA
replication, recombination, and
repair
35 18 14-3-3, adenosine-tetraphosphatase, ATP synthase, ATP5A1, ATP5B, ATP5H, ATPase, caspase,
cytochrome C, cytochrome-c oxidase, FH, G6PD, HSD17B10, Hsp27, Hsp70, Hsp90, HSP,
HSP90AA1, HSPA5, HSPB1, HSPD1, HSPE1, KRT8, LMNB1, LMNB2, MAP2K1/2, MDH2, NFkB
(complex), Pkg, PRDX1, Raf, Rsk, Ubiquitin, VCP, VIM
Cellular movement, cellular
assembly and organisation,
cellular function and
maintenance
32 17 Alpha tubulin, Beta Tubulin, calpain, CaMKII, Cdc2, Collagen type I, Collagen(s), Cytokeratin,
ERK, FLNA, FLNB, Focal adhesion kinase, GANAB, GAPDH, GNB2L1, HISTONE, HSP90AB1,
Integrin, KRT18, Laminin, P4HB, PDGF BB, PHB, PSAT1, RPSA, SERPINH1, Sos, STOML2, TCR,
Tgf beta, TUBA1C, TUBB, Tubulin, VDAC1, YWHAG
Molecular transport, RNA
traﬃcking, protein synthesis
18 11 60S ribosomal subunit, ANKRD13B, BRD7, C15orf39, CHD1L, DAZ1/DAZ4, DAZAP1, DAZL,
DPP7, EIF4A1, EIF4H, H3F3C, HIST3H2A, HIST3H2BB, HNRNPA3, MPC2, MRPL12, MT-ND2,
MYLK3, MYLK, PKP1, RBMXL1, RCHY1, RPL14, RPL17, RPL21, RPL34, RPL39, RPL26L1, RPLP1,
SARNP, SYPL1, THOC6, TSPY8, UBC
KellyCis83 RNA post-transcriptional
modiﬁcation, molecular
transport, protein traﬃcking
60 27 CBX5, DDX1, DDX17, E2f, EIF3C/EIF3CL, FUBP1, GANAB, GAP43, HIST2H2AB, HIST3H2BB,
Histone H1, Histone h4, HNRNPH3, HNRNPK, HNRNPM, HNRNPU, IGF2BP1, KPNA2, MATR3,
NEDD8, NFkB (complex), NHP2L1, PEBP1, PTBP1, RAN, Ribosomal 40s subunit, RNA
polymerase II, Rnr, RPS7, RPS27A, RPSA, RUVBL2, SFPQ, thymidine kinase, XRCC5
Cellular assembly and
organisation, cellular function
and maintenance, tissue
development
47 23 14-3-3, Actin, Akt, Alpha tubulin, Beta Tubulin, BLVRA, CCT2, CCT4, CCT7, CHGA, CLTC,
DPYSL2, EEF2, EIF4A, EIF4H, ENAH, F Actin, FSCN1, GPI, Importin alpha, MAP1B, PDIA6,
PFDN2, PFDN5, PFN1, PFN2, PP2A, Proﬁlin, Rock, SEPT2, STMN1, TUBB, TUBB2B, Tubulin,
YWHAZ
Haematological disease,
immunological disease,
inﬂammatory disease
46 22 14-3-3 (β,ε,ζ), adenosine-tetraphosphatase, ALDH2, aldo, ATP synthase, ATP5A1, ATP5B,
ATP5J, ATP6V1A, ATPase, CDC37, creatine kinase, cytochrome-c oxidase, EEF1B2, ERK1/2, FH,
GAPDH, hemoglobin, Hsp70, HSP, HSPA9, HSPD1, HSPE1, MDH2, PDGF (family), PDIA3, PHB,
PRDX1, PRDX2, Rsk, STIP1, STOML2, TKT, VDAC2, YWHAE
Hereditary disorder,
neurological disease,
psychological disorders
28 15 ACAT1, ADRB, ALDOA, ALDOC, BCR (complex), caspase, Dynamin, EEF1A2, EIF2S1, ERK,
HSPA5, IDH1, Ikb, Immunoglobulin, Insulin, Ldh, LDHB, LDL, MAP2K1/2, Mek, NME1, p70 S6k,
PAFAH1B3, PGK1, PITPNB, Pkc(s), PP1 protein complex group, Proinsulin, RANBP1, RCN1, Sos,
STAT5a/b, TCR, Ubiquitin, YWHAB
Cancer, gastrointestinal
disease, hepatic system disease
22 13 26s Proteasome, AMPK, BASP1, Calmodulin, calpain, CaMKII, CD3, CRABP1, cytochrome C,
EIF4A2, ENO1, estrogen receptor, EWSR1, FLNC, FSH, GSTP1, Histone h3, Hsp90, HSP90AB1,
HSPA8, Interferon alpha, Jnk, Lh, Mapk, P38 MAPK, p85 (pik3r), PHB2, PI3K (complex), Pka,
PKM, PLC gamma, Rb, VCP, Vegf, VIM
SK-N-ASCis24 Haematological disease,
immunological disease,
inﬂammatory disease
56 25 ACTB, ACTN1, Akt, ALB, Alpha actin, Beta Tubulin, CFL2, DAZAP1, F Actin, G-Actin, GAPDH,
Growth hormone, HIST1H2BB, HNRNPA3, HNRNPD, KHSRP, KRT8, Lamin b, Ldh, LDHA,
LDHB, LIMA1, LUC7L2, NASP, NEDD8, PI3K (family), PLEC, PRDX1, PRDX6, Spectrin, SPTAN1,
SPTBN1, TUBA1C, TUBB, YWHAG
Developmental disorder,
gastrointestinal disease,
hepatic system disease
31 16 ADAMTS4, ANXA11, B4GALT1, BROX, CHMP4B, CNPY2, CNPY3, CTH, CYB5R1, DPP8, EIF4A1,
IDO1, IL10RA, ITPRIPL1, JAG1, KIAA1967, KLF6, MXRA7, NOTCH2, NPR1, NT5E, PTMA, RPLP2,
SARNP, SCAF1, SEPT9, SP7, SRP9, TNF, TPI1, TSC22D3, UBC, UBE2V2, UBQLN4, VAT1
Cell morphology, cellular
function and maintenance,
DNA replication,
recombination, and repair
31 16 14-3-3, 26s Proteasome, Actin, Alpha tubulin, BCR (complex), caspase, Cdc2, Cytokeratin, E2f,
FUBP1, HISTONE, HLA-A, Hsp27, Hsp70, Hsp90, HSPA5, HSPB1, Ifn, KPNA2, KRT18, MHC Class
I (complex), NAA10, NAP1L1, NFkB (complex), NPM1, PDIA4 ,PHB, Pmca, PSME1, PTMA, Rnr,
RPS3, S100A10, Ubiquitin, VIM
Amino acid metabolism, post-
translational modiﬁcation,
small molecule biochemistry
26 14 ACTN4, Alpha Actinin, Alpha catenin, C1q, calpain, CALR, COL1A1, Collagen Alpha1, Collagen
type I, Collagen type III, Collagen type IV, Collagen(s), CTTN, ERK1/2, Fibrinogen, Integrin,
Integrin alpha 2 beta 1, Integrin alpha 5 beta 1, ITGA2, ITGB1, JINK1/2, Laminin, LAP3, Lfa-1,
NME2, P4HA1, P4HB, PDGF (family), PDIA3, PDIA6, Talin, Tap, TPD52L2, VCL, Vla-4
Cellular movement, nervous
system development and
function, cellular function and
maintenance
22 13 ACTC1, AHNAK, Ap1, ATPase, BASP1, Calmodulin, CaMKII, CD3, CD44, Ck2, Coﬁlin, CRABP2,
Creb, ERK, FASN, Focal adhesion kinase, HNRNPA1, HNRNPR, MAP2K1/2, Mlc, MYH9, MYL6,
MYL12B, P38 MAPK, p70 S6k, PDGF BB, PFN1, PGK1, PLC gamma, PP2A, Ras, Rock, Sos, TCR,
Tgf beta
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resistant cell sublines were 1.3–2.8-fold higher in response to
topoisomerase inhibitors than that of their respective parental cell
lines. This is consistent with published data demonstrating that
cisplatin can induce cross resistance to multiple drugs both in vitro
[24,25] and in clinical settings [23,26]. No signiﬁcant changes were
detected for an alkylating drug, temozolomide across all three re-
sistant cell lines. Hence, the observed signiﬁcant resistance to
irinotecan, which is currently used routinely for relapsed high risk
neuroblastoma [27], may provide vital information on the poten-
tial mechanisms of resistance to the re-initiation therapy.
Despite signiﬁcant phenotypic changes, increased invasive-
ness, accumulation of genomic aberrations and altered protein
expression, no signiﬁcant difference in the IC50 of CHP-212Cis100
compared to its parental cell line was detected, which may be due
A B C
Fig. 3. Cisplatin regulator network analysis. IPA prediction of upstream molecules in cisplatin regulator network activation from the modulated protein datasets. (A) CHP-
212Cis100, (B) KellyCis83 and (C) SK-N-ASCis24. Legend key of IPA prediction is in the right corner.
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Fig. 4. Epithelial to mesenchymal transition markers. (A) Representative image of western blot analysis of three cisplatin resistant and sensitive cell line pairs using the
indicated antibodies. TWIST1, SNAI1 and ZEB1 were probed on the same blot. Typically, 5 μg of protein extract was loaded per well, equal loading was conﬁrmed by Coomassie
blue staining (Supplementary File S4). (B) The fold change in protein expression of drug resistant cells compared to their parental counterparts was quantiﬁed by densito-
metric analysis of two biological repeat experiments, normalised against endogenous control ACTB.
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Fig. 5. Mesenchymal phenotype. (A) Common proteins in common IPA pathways. (B) Representative image of western blot analysis of three cisplatin resistant and sensitive cell
line pairs using the indicated antibodies. MYH9, MYL12B, ACTB were probed on the same blot, while VIM and ACTB on the other and TUBA separately. Typically, 5 μg of protein
extract was loaded per well, equal loading was conﬁrmed by Coomassie blue staining (Supplementary File S4). (C) The fold change in the protein expression of drug resistant
cells compared to their parental counterparts was quantiﬁed by densitometric analysis of two biological repeat experiments. The red horizontal line represents protein ex-
pression in parental cell lines. Graphed data represent mean values ± SD of three independent experiments. Asterisks indicate statistical signiﬁcance obtained using a paired
Student’s t-test. * p < 0.05, ** p < 0.01, ***p < 0.001, n = 3 for all experiments. (D) Representative image of western blot analysis of SK-N-ASCis24 and SK-N-AS cells with anti-
MYH9, anti-ROCK1 and TUBA antibodies. (E) The fold change in protein expression of drug resistant cells compared to their parental counterpartswas quantiﬁed by densitometric
analysis of two biological repeat experiments, normalised against endogenous control TUBA. The red horizontal line represents protein expression in parental cell lines. Graphed
data representmeanvalues ± SDof three independent experiments. Asterisks indicate statistical signiﬁcanceobtainedusing apairedStudent’s t-test. * p < 0.05, ** p < 0.01, ***p < 0.001.
(F) Immunostaining of SK-N-ASCis24 and SK-N-AS cells with anti-MYH9 and anti-ROCK1 antibodies followed by visualisation with AlexaFluor-647 and Alexa Fluor-488, re-
spectively. Bar, 25 μm.
152 O. Piskareva et al./Cancer Letters 364 (2015) 142–155
to the intrinsic resistance of parental CHP-212 to cisplatin, with IC50s
equal to or greater than those of both the resistant Kelly and SK-
N-AS lines. This high level of intrinsic resistance explains the much
higher concentrations of cisplatin required to select a CHP-212 re-
sistant variant. Little information is available about intrinsic resistance
in neuroblastoma; however the association between chemoresis-
tance and enhanced pro-angiogenic activity has been observed and
deemed relevant for tumor progression [28,29]. It is possible that
the CHP-212 cell line represents a sub-population of cells with in-
trinsic resistance in neuroblastoma, inwhich case the characterisation
of both CHP-212 and CHP-212Cis100 will prove useful for future
studies of drug resistance.
Once drug resistance was conﬁrmed, additional functional effects
were investigated to further characterise the cell lines. Array CGH
conﬁrmed that we had established cisplatin-resistant sublines with
distinct genomic patterns but also retained the typical genomic ab-
errations outlined earlier. No noteworthy genomic alterations were
identiﬁed which could potentially guide us towards major players
in drug resistance, except the focal gain of NAIP on chromosome 5
[5]. The overall increase in the number of chromosomal aberra-
tions was common to all resistant sublines and is consistent with
the literature [16–18,21,30].
The majority of altered proteins belong to cytoskeletal, nucleic
acid binding and chaperone protein families which were detailed
among the altered proteins identiﬁed by comparative proteomics
in different drug resistant cancer cell models [31]. Similar changes
in protein expression were reported for cisplatin [32] and etoposide
resistant neuroblastoma cell line SH-SY5Y [22]. Subsequently, we
further examined themolecular and biological functions of the iden-
tiﬁed proteins using Ingenuity Pathway Analysis software. By their
molecular and cellular function, modulated proteins were mostly
classiﬁed into proteins involved in ‘cell growth and proliferation’
and ‘cell death and survival’. Comparison of the top ﬁve IPA path-
ways for each cisplatin resistant cell line pair demonstrated that of
these ﬁve, four top pathways were common for SK-N-ASCis24 (non-
MNA) and CHP-212Cis100 (MNA), while KellyCis83 shared one
pathway ‘Aldosterone Signaling in Epithelial Cells’ common to
KellyCis83 and CHP-212Cis100 (both MNA). The diversity of path-
ways involved in the development of cisplatin resistance supports
the concept that drug resistant cells can overcome cytotoxic pres-
sure and adapt through establishment of complicated self-defence
mechanisms.
The IPA regulator analysis did not predict signiﬁcant upstream
contributors activated by cisplatin in the development of drug re-
sistance in our models. However, the prediction pointed towards
proteins involved in the development of resistance to other drugs.
The altered expression of beta-tubulin (TUBB), beta-actin (ACTB),
vimentin (VIM) and 78 kDa glucose-regulated protein (HSPA5) in
all three cisplatin resistant cell lines suggests their potential role
in response and cross-resistance to antimicrotubule agents like vin-
cristine [33]. Vimentin was found to be associated with the
development of resistance to etoposide in neuroblastoma cell line
SH-SY5Y [22]. Vimentin is also considered as a canonical marker
of EMT, a cellular re-modelling process in which epithelial cells
acquire characteristics of mesenchymal phenotype leading them to
dramatically change their shape and display increased motility
[8–10,34]. Signiﬁcant upregulation of VIM and downregulation of
cytoskeletal proteins KRT18, KRT8 in SK-N-ASCis24 and CHP212-
Cis100 are consistent with changes associated with epithelial-to-
mesenchymal transition [8–10]. These two cisplatin resistant cell
lines also exhibited a signiﬁcantly increased invasiveness. The knock-
down of cytokeratins, KRT18 and KRT8, alone increased cancer cell
motility and invasionwithoutmodulating EMTmarkers [35]. Another
member of cytokeratin family, KRT19 was highly correlated with
the invasiveness in neuroblastoma cell lines. The study demon-
strated signiﬁcantly lower expression of KRT19 mRNA in stage 4S
tumors, which developmetastases, relative to localised primary neu-
roblastomas, i.e. stage 1 and 2 disease [36]. Hence, the growing body
of evidence supports the idea that EMT plays an important role in
tumor progression and metastasis as well as the development of
chemotherapy resistance [10,37], but it also can be cancer type spe-
ciﬁc [38].
EMT transcription factors such as the TWIST, ZEB and SNAI fami-
lies activate the accrual of mesenchymal markers, like VIM and
repress epithelial markers such as cytokeratins and E-cadherin during
EMT. It is believed that increased production of these transcrip-
tion factors induces EMT thereby triggering migration and invasion.
EMT transcription factors have a signiﬁcant overlap in their regu-
lation, target genes, and mechanism of action (reviewed in [39,40]).
The cross talk between the EMT transcription factors is complicat-
ed and not fully understood. Recent data indicate that ZEB factors
are downstream of the SNAI and TWIST families in the EMT hier-
archy [41]. SNAI1 up-regulates ZEB1 synthesis at both transcriptional
and post-transcriptional levels [42–44]. Expression of TWIST1 and
SNAI1 is mutually dependent although in different directions de-
pending on the cancer type [44–46]. In this study all drug resistant
cell models lost expression of ZEB1 regardless of the expression levels
of SNAI1 and TWIST1 and invasiveness of the cell lines. It pro-
poses a common mechanism by which ZEB1 was switched off. The
observation also suggests that EMT transcription factors may be af-
fected during the development of cisplatin resistance but to different
extents. Of interest is the signiﬁcant downregulation of SNAI1,
TWIST1 and ZEB1, which was registered in the highly invasive drug
resistant SK-N-ASCis24 cell line suggesting other cellular players in
the invasive mechanism.
The highest scores for actin cytoskeletal signalling, ILK signal-
ling, epithelial adherens junction signalling and remodelling of
epithelial adherens junctions in SK-N-ASCis24 are consistent with
the observed changes in morphology and invasiveness of this cell
line. All of these pathways share common cytoskeletal protein fami-
lies, such as integrin, actin and myosin, being active players in
mesenchymal cell migration [11]. Non-muscle myosin II (MYH9),
which was over-expressed by 4-fold in SK-N-ASCis24, is a conven-
tional motor protein known to generate intracellular contractile
forces and tension by associatingwith F-actin and driving cell spread-
ing, migration, cytokinesis, as well as other cellular processes [47–49].
It is considered to be an effector of cell migration and morphogen-
esis [50]. MYH9 activity is regulated by phosphorylation [13,50] by
different kinases including ROCK1 [14]. IPA predicted ROCK1 as a
partner in MYH9 containing network, which also contributes to cell
invasiveness [12]. An increased expression of ROCK1 was corre-
lated with an increased motility and invasiveness in neuroblastoma
[51]. In the present study, we observed an increased invasiveness
of SK-N-ASCis24 cell line associated with an increased expression
of MYH9 and its network partners rather than ROCK1. This obser-
vation can be explained by the mesenchymal phenotype of SK-N-
ASCis24 cells acquired during the development of cisplatin resistance.
The mesenchymal phenotype does not require elevated levels of
ROCK1 for increased cell motility and invasiveness [52].
Our LC–MS data also identiﬁed elevated levels of a-Actinins,
ACTN1 and ACTN4, in the highly invasive SK-N-ASCis24 cell line.
ACTN1 and ACTN4 are members of the spectrin gene superfamily
expressed in non-muscle cells [53,54]. These proteins contribute to
stabilisation of cell adhesion and regulation of cell shape and cell
motility. Recent ﬁndings suggest that ACTN1 and ACTN4 play a role
in the cell motility and invasion in different types of human cancer
including breast [55], bladder [56], colorectal [57], ovarian [58,59]
and brain [60]. In contrast, suppression of tumourigenicity by in-
creased expression of ACTN4was reported in human neuroblastoma
cell line SK-N-BE(2) [61].
In this study, SK-N-ASCis24 cell line acquiredmesenchymal prop-
erties despite the reduced expression of the EMT transcription factors
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SNAI1, TWIST1 and ZEB1. The mesenchymal properties included
ﬁbroblastoid morphology, increased potential for motility and in-
vasion during the development of chemoresistance, which are
prerequisites of EMT [62]. The increased expressions of MYH9 and
ACTN4 were observed in the absence of gene ampliﬁcation, sug-
gesting a potential role for miRNA in their regulation. Our previous
study identiﬁed a panel of 33 downregulated miRNA in SK-N-
ASCis24 [5]. Of the panel, miR-545 and miR-876-3p were predicted
to target both genes (Supplementary File S4). Further investiga-
tion of the functional relationship between miRNA and proteins is
required.
Response to chemotherapy is poor in high risk neuroblastoma,
despite treatment with additional drugs such as topotecan and
temozolomide, due to the development of drug resistance [3].
Proteomics proﬁling of a large cohort of neuroblastoma patients
would help to identify protein signalling pathways to deﬁne the
targets for personalised therapy. It will be critical for the develop-
ment of protein biomarkers of tumour response to chemotherapy
or the development of chemoresistance. It would advance both
current treatment protocols and selection of patients who may be
more likely to beneﬁt from chemotherapy. The drug resistant neu-
roblastoma cell lines described in this study can greatly complement
the clinically identiﬁed protein biomarkers in better understand-
ing the eﬃcacy of treatment regimens and drugs.
Thus, the panel of three different cisplatin resistant neuroblas-
toma cell lines provides a unique and fundamental platform for pre-
clinical studies of the mechanisms underlying the development of
drug resistance as well as discovering new drugs and therapeutic
targets in neuroblastoma.
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